Moreover, the excessive renal activity of NADPH oxidase is considered to be one of the crucial factors for the progress of diabetic nephropathy and the inhibition of this enzyme is widely discussed as a promising new therapeutic strategy [16]. Here, FMO5 is linked to diabetic kidney disease.